By Fineline Cube 
Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant, has entered into a research collaboration with Massachusetts General Hospital (MGH) to jointly advance the application of theranostics.
Collaboration Details
The duo will establish a Therapy Command Center to support MGH and its affiliated centers across Massachusetts, Maine, and New Hampshire in implementing theranostic approaches. The center will be equipped with advanced imaging systems, including long-axial PET/CT, to help MGH collect theranostics-related data, enable real-time monitoring of treatment processes, and assist physicians in developing precise, personalized treatment plans for each patient.
Theranostics Application
Theranostics—an approach that uses radiopharmaceuticals for both disease diagnosis and therapy—has been widely adopted for treating specific cancers such as thyroid cancer, prostate cancer, and neuroendocrine tumors (NETs). Typically, molecular imaging plays a key role in theranostics by facilitating disease staging assessment and treatment response monitoring.-Fineline Info & Tech